



Test4TRK™

Bayer-sponsored *NTRK* Testing Program for RAI-R DTC Patients
Enroll your RAI-R DTC patients for *NTRK* testing at NO COST

***NTRK* Gene Fusions are Significantly More Common in RAI-R DTC¹**

Among radioactive iodine refractory differentiated thyroid carcinoma (RAI-R DTC), a higher prevalence of ***NTRK* gene fusions** is found.¹ Studies suggest *NTRK* gene fusions are estimated to be found in approximately 2.4%-12%^{2,3a} of DTC patients and more commonly in RAI-R cases.¹

Test Your RAI-R DTC Patients Now to Identify an Actionable Driver and Potential Treatment Options

Genomic cancer testing is the best method to uncover if an *NTRK* gene fusion is driving the tumor. Test results may aid in treatment decisions and patient management.⁴

Bayer will cover the cost of the test regardless of insurance coverage, test results and treatment decision.



Take Three Easy Steps to Participate in the Program

- 1** Complete the Test Requisition Form included within this brochure.
- 2** Request a shipment kit or submit the tissue sample directly to NeoGenomics Laboratories along with your patient's completed form.
- 3** Review results (expect within 14 calendar days after receipt of the patient's specimen at NeoGenomics) and discuss potential treatment options with your patient.

^aPapillary thyroid carcinoma (12% based on a Polish population).



Tell me more...

What is an *NTRK* gene fusion?

A genomic cancer test can identify an *NTRK* gene fusion. This is where an *NTRK* gene fusion joins together, or fuses, with a different gene. *NTRK* gene fusions are the cause of TRK fusion cancer, which is a term used to describe a variety of common and rare cancers.⁵⁻⁷ Research has identified *NTRK* gene fusions in more than two dozen types of common and rare solid tumors.⁵⁻⁸

ABOUT THE PROGRAM

What is the Test4TRK testing program?

Test4TRK is a Bayer-sponsored program offering laboratory testing for *NTRK* gene fusions (histology and molecular subject to tissue availability) to eligible thyroid cancer patients at no cost. The test results provide information on whether the tumor harbors an actionable *NTRK* fusion as a driver, which may aid in the treatment decision for your patient.

Bayer will cover the full cost of the test regardless of insurance coverage, test results and treatment decision.

What test will be done and what does it test for?

All eligible patients who enroll and opt-in to Test4TRK will receive an RNA-based next-generation sequencing (NGS) based, *NTRK* NGS Fusion Profile, from NeoGenomics. Patients with an adequate tumor tissue sample will also receive a NeoGenomics Pan-Tropomyosin receptor kinase (TRK) Immunohistochemistry (IHC) test.

ABOUT PATIENT ELIGIBILITY & PAYMENT

Who is eligible for the Test4TRK program?

Any patient with radioactive iodine refractory differentiated thyroid carcinoma (RAI-R DTC) with adequate tumor tissue available for testing is eligible to enroll in the Test4TRK program. Patients who have not previously undergone a biopsy may still enroll in the program but are responsible for working with their physician to extract a viable tumor specimen and cover any associated expenses. Bayer will not cover the associated costs of extracting a viable tumor specimen.

What type of insurance coverage do my patients need to participate?

Any RAI-R DTC patient is eligible for Test4TRK regardless of insurance coverage.

Will there be any cost to my patient?

There will be NO COST for patients, healthcare providers or insurance companies for the NGS-based or IHC test.

What if I get a bill?

No bill will be sent to patients, healthcare providers or beneficiaries who participate in this program. If a bill is received in error, please discard or contact 866-776-5907 (option 3).

ABOUT NEXT STEPS

We submitted the test and received the results, now what?

Following a report on the test results, talk to your patient about a potential treatment plan based on the *NTRK* gene fusion status identified.

Where can I find more information or order more Test Requisition Forms?

Contact your Bayer sales consultant at 800-633-3796 or NeoGenomics at 866-776-5907 (option 3) for more information. Additional forms can be downloaded at www.Test4TRK.com.

References:

1. Van der Tuin K, Ventayol Garcia M, Corver WE, et al. Targetable gene fusions identified in radioactive iodine refractory advanced thyroid carcinoma. *Eur J Endocrinol*. 2019;180(4):235-241. doi:10.1530/EJE-18-0653.
2. Strzaski N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. *Nat Commun*. 2014;5:4846. doi:10.1038/ncomms5846.
3. Brzezińska E, Karbownik M, Migdalska-Sek M, Pastuszek-Lewandoska D, Wloch J, Lewiński A. Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population. *Mutat Res*. 2006;599(1-2):26-35.
4. Hechtman JF, Benayed R, Hyman DM, et al. Pan-trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. *Am J Surg Pathol*. 2017;41(11):1547-1551.
5. Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. *ESMO Open* 2016;1:e000023. doi:10.1136/esmoopen-2015-000023.
6. Kumar-Sinha C, Kalyana-Sundaram S, Chinnaiyan AM. Landscape of gene fusions in epithelial cancers: seq and ye shall find. *Genome Med*. 2015;7:129. doi:10.1186/s13073-015-0252-1.
7. Vaishnavi A, Le AT, Doebele RC. TRKING down an old oncogene in a new era of targeted therapy. *Cancer Discov*. 2015;5(1):25-34.
8. Lange AM, Lo H-W. Inhibiting TRK proteins in clinical cancer therapy. *Cancers*. 2018;10(4):E105. doi:10.3390/cancers10040105.

© 2020 Bayer. All rights reserved. Bayer and the Bayer Cross are registered trademarks of Bayer and Test4TRK is a trademark of Bayer.

© 2020 NeoGenomics Laboratories, Inc.

04/2020 | PP-PF-ONC-US-1202-1

